ArticleDeutsches Arzteblatt international2025
Psychoactive Substance Use in Germany: Findings From the Epidemiological Survey of Substance Abuse (ESA) in 2024.
Article in Deutsches Arzteblatt international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- [Inpatient treatment of substance use disorders : Structures and treatment strategies: results of a nationwide survey of treatment facilities].Der Nervenarzt · 2026Article
- Recommendations on Switching or Deprescribing Hypnotic Medications for Insomnia.Deutsches Arzteblatt international · 2026Review
- Attitudes of Patients with Non-Psychotic Mental Disorders Towards Cannabis After Its Legalization-Comparison with Patients Before Legalization.Brain sciences · 2026Article
- Who is at risk? Core mental health symptoms and problematic cannabis use in Germany.Journal of cannabis research · 2026Article
- Addictions in Hidradenitis Suppurativa: A Cross-Sectional Pilot Study.Dermatology and therapy · 2026Article
- Short-term effects of cannabis legalisation in Germany on driving under the influence of cannabis: a difference-in-differences analysis using Austria as a control.The Lancet regional health. Europe · 2026Article
- Fatherhood and addictive disorders: experiences and support needs - results of a qualitative interview study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonitoring the use of psychoactive substances and the prevalence of substance-related disorders in the general population enables estimation of the extent of substance abuse and its effects on health and society.
methodsData are from the Epidemiological Survey of Substance Abuse (ESA) for 2024 (n = 7534, aged 18-64 years). Prevalence rates were calculated for the use of tobacco, alcohol, cannabis, illegal drugs, and medications, and for individuals who met the DSM-IV criteria for dependency or abuse. Rates were extrapolated to the German resident population aged 18 to 64 (51 480 168 people).
resultsThe most commonly used substance was alcohol, with a 30-day prevalence of 68.6% (35.3 million people), followed by nonopioid analgesics (31.5%) and conventional tobacco products (21.8%). The 12-month prevalence of cannabis use was 9.8% (5.1 million people). Dependence prevalences were 4.2% for alcohol, 8.3% for tobacco, 1.0% for cannabis, 0.1% for amphetamines, 0.1% for cocaine, 2.8% for analgesics, and 1.5% for hypnotics and sedatives. Abuse prevalences were 5.6% for analgesics, 0.5% for cannabis, 0.1% for cocaine, 0.1% for amphetamines, 1.1% for hypnotics and sedatives, and 3.3% for alcohol.
conclusionThe use of psychoactive substances in Germany is still widespread. Because of the effects of psychoactive substance use on health and society, continual monitoring is essential for the early detection of trends and the institution of targeted preventive and interventional measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.